Spectrum Pharmaceuticals (NASDAQ:SPPI) Files An 8-K

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that independent director Luigi Lenaz, M.D., has been appointed to the newly created position of Lead Director.

Story continues below

“Dr. Lenaz’s unique scientific background and deep business expertise make him ideally suited for the newly created Lead Director position,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “Dr. Lenaz has provided invaluable advice historically, and I look forward to working closely with him in his new role.”

Luigi Lenaz, M.D. is a world-renowned oncologist and a leading scientist authority in developing cancer drugs. An accomplished oncologist before joining the industry, he has conducted research at prominent institutions including Roswell Park Memorial Institute, Memorial Sloan-Kettering Cancer Center, and the National Cancer Institute in Milan. He is an experienced anti-cancer drug developer, with over 40 years of experience in the pharmaceutical industry and has played key roles in developing numerous major cancer drugs including Taxol®, Adriamycin®, etoposide, amascrine, cisplatin, and carboplatin. Dr. Lenaz served as a Post Doctoral Fellow at both the Memorial Sloan-Kettering Cancer Center in New York and the National Cancer Institute in Milan, Italy. He received his medical degree at the University of Bologna Medical School in Bologna, Italy in 1966.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrum’s strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

An ad to help with our costs